Medpace Holdings, Inc.
At today's price, Medpace Holdings, Inc. (MEDP) is priced for +33.5% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
Medpace is a contract research organization that runs clinical trials for biotech and pharma. The business is debt-free and cash-generative, holding about $653 million of net cash and shrinking its share count roughly 5.5% a year through buybacks. Q1 2026 revenue grew 26.5% to $706.6 million and EPS of $4.28 beat the $3.92 estimate. The market is focused on the order book, not the print. Net new business awards produced a book-to-bill of 0.88 (below the 1.0 line that keeps backlog growing), and
Is MEDP overvalued? See what's priced in →
707 institutional managers reported holding MEDP in 13F filings for the quarter ended 2026-03-31. Together they hold about 83% of the company; the top 10 hold 36%. 74 opened new positions that quarter. Held by BlackRock, Vanguard Group, AQR Capital, among others. On the short side, 2.1M shares were sold short as of the 2026-06-15 count, about 7% of shares outstanding (8.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
MEDP has cut its share count 20.8% over the past five years, spending $2.09B on repurchases. It pays no dividend. Cash returned over the past three years: $1.09B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at MEDP over the trailing three years: 2025: 1 buy totaling $1k. 9 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
MEDP's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-26 | +4.6% | -3.3% |
| 2023-10-25 | +18.8% | +20.7% |
| 2024-02-14 | +11.6% | -1.9% |
| 2024-04-24 | +9.4% | +1.9% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
MEDP's latest 8-K filings: 2026-06-04 (items 5.02); 2026-05-19 (items 5.03, 5.07, 9.01); 2026-04-22 (items 2.02, 5.02, 9.01); 2026-02-09 (items 2.02, 9.01); 2025-10-22 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.